BOSTON--(BUSINESS WIRE)--Nov. 21, 2024--
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc.
On November 20, 2024, Dr. Han received a non-qualified stock option grant to purchase 95,000 shares of PepGen’s common stock, par value $0.0001 per share, with an exercise price of $4.40 per share, the closing price of PepGen’s common stock as reported by The Nasdaq Global Select Market on November 20, 2024. The inducement grant stock option has a ten-year term and is scheduled to vest over four years, with 25% of the shares vesting on the one-year anniversary of Dr. Han’s employment commencement date and the remainder vesting in equal monthly installments over the following three years, subject to Dr. Han’s continued service to PepGen through the applicable vesting dates.
This inducement grant was granted outside of PepGen’s stockholder-approved equity incentive plans pursuant to PepGen’s 2024 Inducement Plan, which was adopted by PepGen’s Board of Directors in August 2024. This award was approved by the Compensation Committee of the Board of Directors, which consists entirely of independent directors, as a material inducement to Dr. Han’s entering into employment with PepGen in accordance with Nasdaq Listing Rule 5635(c)(4).
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121499632/en/
Investor
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
